Valuation: Scholar Rock Holding Corporation

Market Cap 6.34B 5.49B 5.15B 4.7B 8.83B 605B 8.96B 60.54B 23.67B 303B 23.81B 23.29B 1,010B P/E 2026 *
-15.7x
P/E 2027 * -20.3x
Enterprise Value 5.94B 5.14B 4.82B 4.4B 8.26B 566B 8.39B 56.68B 22.16B 284B 22.29B 21.81B 945B EV / Sales 2026 *
995x
EV / Sales 2027 * 40.2x
Free-Float
99.23%
Yield 2026 *
-
Yield 2027 * -
1 day+3.36%
1 week+12.43%
Current month+13.80%
1 month-1.61%
3 months+9.41%
6 months+15.35%
Current year+22.18%
1 week 47.99
Extreme 47.99
54.7
1 month 45.73
Extreme 45.73
56.96
Current year 38.75
Extreme 38.75
58.49
1 year 27.07
Extreme 27.07
58.49
3 years 5.93
Extreme 5.93
58.49
5 years 4.32
Extreme 4.325
58.49
10 years 4.32
Extreme 4.325
70
Manager TitleAgeSince
Chief Executive Officer 59 2025-04-26
Director of Finance/CFO 62 2025-04-26
Chief Operating Officer 58 2025-04-26
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 53 2014-07-31
Director/Board Member 78 2016-09-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Director

-2,544 0.0022%
7/1/26 Sell

Director

-5,446 0.0047%
7/1/26 Sell

Director

-3,053 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
+3.36%+12.43%+67.14%+655.90% 6.34B
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+4.53%+37.56%+67.36% 54.05B
-0.22%+33.59%+8.43%+493.18% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
-0.06%+0.61%-16.45%-13.68% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+8.47%+50.06%-20.09% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
-1.85%-11.15%+32.75%+134.22% 12.72B
Average +0.23%+9.19%+59.38%+247.38% 27.31B
Weighted average by Cap. +0.09%+10.09%+56.58%+177.71%

Financials

2026 *2027 *
Net sales 5.97M 5.17M 4.85M 4.42M 8.31M 569M 8.44M 56.99M 22.28M 285M 22.41M 21.93M 951M 149M 129M 121M 110M 207M 14.17B 210M 1.42B 554M 7.09B 558M 546M 23.65B
Net income -443M -384M -360M -328M -617M -42.26B -626M -4.23B -1.65B -21.16B -1.66B -1.63B -70.56B -362M -313M -294M -268M -504M -34.51B -511M -3.45B -1.35B -17.28B -1.36B -1.33B -57.62B
Net Debt -405M -350M -328M -300M -563M -38.58B -572M -3.86B -1.51B -19.32B -1.52B -1.49B -64.42B -374M -324M -304M -277M -521M -35.68B -529M -3.57B -1.4B -17.87B -1.4B -1.37B -59.58B
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Employees
289
Date Price Change Volume
26-08-12 US$53.82 +3.36% 899,240
26-08-11 US$52.07 +0.35% 853,904
26-08-10 US$51.89 -1.95% 827,075
26-08-07 US$52.92 +0.53% 958,437
26-08-06 US$52.64 +9.96% 1,617,161
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
52.07USD
Average target price
59.94USD
Spread / Average Target
+15.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SRRK Stock